Granix Approval History
FDA Approved: Yes (First approved August 29, 2012)
Brand name: Granix
Generic name: tbo-filgrastim
Dosage form: Injection
Company: A-S Medication Solutions, LLC
Treatment for: Neutropenia Associated with Chemotherapy
Granix (tbo-filgrastim) is a leukocyte growth factor indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.
Development History and FDA Approval Process for Granix
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.